《新股表现》加科思药业(01167.HK)暗盘高开18%报16.48元
根据辉立交易平台显示,下周一(21日)挂牌的加科思药业(01167.HK)暗盘高开17.7%报16.48元获承接,现造20.9元,较上市价14元,高49%,成交100万股。
加科思是一家仍处於临床阶段制药公司,专注於创新肿瘤疗法自主研发。是次上市共发售9,647.61万股,并已引入包括LAV Funds、Matthews Funds、哈德逊湾资本、Octagon Investments等6名基石投资者,合共认购3,322.08万股;其中10%公开发售获逾298倍超购,已启动回拨机制占比增至50%,认购一手中签率15%,股份以招股范围(12-14元)上限定价,料集资净额约12.63亿元,其中88%用作产品的临床开发和商业化,8%用於建造符合GMP标准内部生产设施。上市联席保荐人分别为高盛及中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.